ArticleScientific reports2026
Prediction of SARS-CoV-2 exposure through T cell activation profiles.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Reactogenicity and Immunogenicity of Adjuvanted and Nonadjuvanted RSV Vaccines in Solid Organ Transplant Recipients.Transplantation direct · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the ongoing effort to study the SARS-CoV-2 virus and COVID-19 disease, assessment of the T cell immune response has guided vaccine and therapeutic development. T cell immunity, as measured by T cell activation, is commonly assessed by the activation induced marker (AIM) assay. However, no concerted effort has been made to compare AIM pairs and identify those that best detect T cell activation. The emergence of SARS-CoV-2 provided unique access to both known naïve and COVID-19 convalescent donor samples for the comparison of 35 unique T cell AIM pairs using a 15-marker flow cytometry panel. Detailed comparative analysis identified top performing AIM pairs and informed the development of a machine learning algorithm that predictively classified samples as COVID-19 convalescent or naïve. This approach may be additionally applicable to the assessment and prediction of T cell antigen reactivity in cancer and autoimmune disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.